Home » Stocks » Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc. (SBPH)

Stock Price: $1.25 USD -0.15 (-10.71%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
After-hours: $1.33 +0.08 (6.40%) Oct 20, 5:17 PM

Stock Price Chart

Key Info

Market Cap 21.56M
Revenue (ttm) n/a
Net Income (ttm) -29.07M
Shares Out 17.25M
EPS (ttm) -1.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $1.25
Previous Close $1.40
Change ($) -0.15
Change (%) -10.71%
Day's Open 1.40
Day's Range 1.25 - 1.40
Day's Volume 80,251
52-Week Range 0.80 - 4.80

More Stats

Market Cap 21.56M
Enterprise Value 857,625
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 17.25M
Float 15.88M
EPS (basic) -1.74
EPS (diluted) -1.75
FCF / Share -1.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 77,617
Short Ratio 1.16
Short % of Float 0.49%
Beta 1.05
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.03
Revenue n/a
Operating Income -28.43M
Net Income -29.07M
Free Cash Flow -26.32M
Net Cash 20.70M
Net Cash / Share 1.20
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -40.31%
ROE -81.68%
ROIC -76.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

Current: $1.25
Target: 1.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth----62.79%28.18%-
Gross Profit---0.350.950.74
Operating Income-33.02-28.47-21.25-19.40-11.60-7.81
Net Income-24.10-22.85-27.68-17.37-11.56-9.71
Shares Outstanding16.4514.3711.157.265.683.12
Earnings Per Share-1.46-1.88-2.48-2.39-2.03-3.11
Operating Cash Flow-29.06-25.24-17.68-15.82-8.21-7.38
Capital Expenditures-0.27-1.97-0.32-0.21-0.39-0.06
Free Cash Flow-29.33-27.22-18.01-16.03-8.60-7.43
Cash & Equivalents54.6947.8751.0424.739.681.57
Total Debt22.29-----
Net Cash / Debt32.4047.8751.0424.739.681.57
Book Value35.5355.8634.7517.0211.0312.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Spring Bank Pharmaceuticals, Inc.
Country United States
Employees 30
CEO Martin J. Driscoll

Stock Information

Ticker Symbol SBPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SBPH
IPO Date May 6, 2016


Spring Bank Pharmaceuticals, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.